Discuss This Drug

vibegron

CHEBI:CHEBI_142418

Definition

A pyrrolopyrimidine obtained by formal condensation of the carboxy group of (6S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxylic acid with the amino group of (R)-[(2R,5S)-5-(4-aminobenzyl)pyrrolidin-2-yl](phenyl)methanol. It is a beta3-adrenergic receptor agonist currently in clinical development for the treatment of patients with overactive bladder.

Chemical Information

Molecular Formula
C26H28N4O3
Molecular Mass
444.527
Charge
0
SMILES
C(NC1=CC=C(C=C1)C[C@@H]2CC[C@@H](N2)[C@@H](C3=CC=CC=C3)O)([C@H]4N5C(C=CN=C5CC4)=O)=O
InChI
InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
InChIKey
DJXRIQMCROIRCZ-XOEOCAAJSA-N

Alternative Names

  • (6S)-N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide
  • Beova
  • MK-4618
  • vibegron
  • vibegronum

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

core#notation
CHEBI:142418
DRON_00010000
2472254
oboInOwl#hasDbXref
Reaxys:19541234

Additional References

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

core#notation
CHEBI:142418
oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
2472254
oboInOwl#hasDbXref
Reaxys:19541234
oboInOwl#id
CHEBI:142418
generic_name
Vibegron
rxcui
2472321
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
listing_expiration_date
20241231
route
ORAL
dosage_form
POWDER
active_ingredient_strength
1 kg/kg
nui
N0000185007
pharm_class_epc
beta3-Adrenergic Agonist [EPC]
pharm_class
Adrenergic beta3-Agonists [MoA]
pharm_class_moa
Adrenergic beta3-Agonists [MoA]
marketing_start_date
20230527
package_marketing_start_date
27-MAY-23
brand_name
GEMTESA
brand_name_base
GEMTESA
product_ndc
50379-0027
application_number
NDA213006
labeler_name
Porton Fine Chemicals Ltd
manufacturer_name
Sumitomo Pharma America, Inc.
spl_id
22ca9715-b348-4bcb-e063-6394a90ae1ef
active_ingredient_name
VIBEGRON
package_ndc
50379-0027-1
package_description
60 kg in 1 DRUM (50379-0027-1)
unii
M5TSE03W5U
spl_set_id
25f21d25-14f8-4fda-91f6-7aa8b68aa1c8
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_35522
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
has_treatment
http://purl.obolibrary.org/obo/DOID_0111671
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect5276
owl#annotatedSource
t112519
owl#someValuesFrom
t3866016